Skip to main content
SpringerLink
Log in

Eosinophilic Pneumonia in Patients Treated with Daptomycin

Review of the Literature and US FDA Adverse Event Reporting System Reports

  • Short Communication
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Eosinophilic pneumonia (EP) has been noted in association with daptomycin use. The product labelling was recently updated to include EP in the Warnings and Precautions and Post-Marketing Experience sections.

Objective: The objective of this study was to analyse adverse event (AE) reports submitted to the US FDA as well as published cases to characterize the clinical features and course of EP in daptomycin-treated patients.

Methods: We searched for EP cases associated with daptomycin administration in the FDA Adverse Event Reporting System (AERS) submitted from 2004 to 2010, and the published literature. Cases were defined as definite, probable, possible and unlikely in terms of the diagnosis of EP and the potential association with daptomycin exposure. Definite cases had concurrent exposure to daptomycin, fever, dyspnoea with increased oxygen requirement or required mechanical ventilation, new infiltrates on chest imaging, bronchoalveolar lavage with >25% eosinophils and clinical improvement following daptomycin withdrawal. Additionally, we assessed inpatient daptomycin utilization.

Results: We identified 7 definite, 13 probable, 38 possible cases of daptomycin-induced EP, and 23 unlikely cases. The seven definite EP cases had resolution after daptomycin was stopped, including two with EP recurrence following daptomycin rechallenge. Regarding the definite cases: (i) ages ranged from 60 to 87 years; (ii) dosing ranged from 4.4 to 8.0 mg/kg/day; and (iii) EP developed 10 days to 4 weeks after starting daptomycin. There was a gradual increase in the number of patients with an inpatient hospital discharge billing for daptomycin from the year 2004 to 2010.

Conclusions: We report 7 definite, 13 probable and 38 possible EP cases associated with daptomycin administration. As AERS is based on voluntary reporting, the incidence of EP cannot be assessed. Healthcare providers should have heightened awareness of this serious AE associated with daptomycin use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Fig. 1

References

  1. Cubicin® (daptomycin) package insert [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021572s011lbl.pdf [Accessed 2011 Mar 7]

  2. Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 2010 Mar 1; 50(5): 737–40

    Article  PubMed  Google Scholar 

  3. US Food and Drug Administration. FDA drug safety communication: eosinophilic pneumonia associated with the use of Cubicin (daptomycin) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm. [Accessed 2011 Mar 7]

  4. Cubicin® (daptomycin) package insert [online]. Available from URL: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=33819&CFID=34544153&CFTOKEN=4f551a4fa2efe2ed-90AB5A7F-F192-598D-C4B9E24D7FDD2672&jsessionid=ca3058b14dc53f534545 [Accessed 2011 Mar 7]

  5. Kosmidis C, Levine DP. Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 2010 Mar; 11(4): 615–25

    Article  PubMed  CAS  Google Scholar 

  6. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008 Apr 15; 46(8): 1142–51

    Article  PubMed  CAS  Google Scholar 

  7. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005 Jun 15; 191(12): 2149–52

    Article  PubMed  CAS  Google Scholar 

  8. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization [online]. Available from URL: http://www.meddramsso.com/ [Accessed 2011 Mar 7]

  9. Philit F, Etienne-Mastroianni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002 Nov 1; 166(9): 1235–9

    Article  PubMed  Google Scholar 

  10. Allen JN. Drug-induced eosinophilic lung disease. Clin Chest Med 2004 Mar; 25(1): 77–88

    Article  PubMed  Google Scholar 

  11. Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005 Jul; 60(7): 841–57

    Article  PubMed  CAS  Google Scholar 

  12. Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med 2006 Apr; 27(2): 192–7

    Article  PubMed  Google Scholar 

  13. Hayes Jr D, Anstead MI, Kuhn RJ. Eosinophilic pneumonia induced by daptomycin. J Infect 2007 Apr; 54(4): e211–3

    Article  PubMed  Google Scholar 

  14. Kakish E, Wiesner AM, Winstead PS, et al. Acute respiratory failure due to daptomycin induced eosinophilic pneumonia. Respir Med CME 2008; 1: 235–7

    Article  Google Scholar 

  15. King TE. Idiopathic acute eosinophilic pneumonia. Up-ToDate®. Topic last updated December 1, 2009 [online]. Available from URL: http://www.uptodate.com/contents/idiopathic-acute-eosinophilic-pneumonia?source=search_result&search=%22Idiopathic+acute+eosinophilic+pneumonia%22&selectedTitle=1%7E150 [Accessed 2010 Mar 1]

  16. Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 2002; 25(6): 381–92

    Article  PubMed  CAS  Google Scholar 

  17. Surveillance Data Inc. (SDI), Inpatient Healthcare Utilization System (IHCarUS). Years 2004–2010. Data extracted September 2011

  18. Kalogeropoulos AS, Tsiodras S, Loverdos D, et al. Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature. J Med Case Reports 2011 Jan 17; 5(1): 13 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033840/pdf/1752-1947-5-13.pdf [Accessed 2011 October 24]

    Article  Google Scholar 

  19. Miller BA, Gray A, Leblanc TW, et al. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis 2010 Jun 1; 50(11): e63–8

    Article  PubMed  CAS  Google Scholar 

  20. Shinde A, Seifi A, DelRe S, et al. Daptomycin-induced pulmonary infiltrates with eosinophilia. J Infect 2009 Feb; 58(2): 173–4

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Ana Szarfman for her feedback related to the data mining analysis. MedDRA® is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

The views expressed in this report are those of the authors and do not necessarily represent the views of the US FDA.

The information discussed in this manuscript was presented, in part, at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, 12–15 September 2010, Session No. 251, Presentation No. L1-2207.

The authors declare no conflicts of interest and their work was independent of financial support.

Author information

Authors and Affiliations

  1. Center for Drug Evaluation and Research, Office of Antimicrobial Products, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA

    Peter W. Kim MD, MS & Sumathi Nambiar

  2. Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland, USA

    Alfred F. Sorbello, Ronald T. Wassel, Tracy M. Pham & Joseph M. Tonning

Authors
  1. Peter W. Kim MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfred F. Sorbello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald T. Wassel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tracy M. Pham
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joseph M. Tonning
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sumathi Nambiar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter W. Kim MD, MS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, P.W., Sorbello, A.F., Wassel, R.T. et al. Eosinophilic Pneumonia in Patients Treated with Daptomycin. Drug Saf 35, 447–457 (2012). https://doi.org/10.2165/11597460-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11597460-000000000-00000

Keywords

Search

Navigation